Evaluation of Visual Outcomes of Monovision Patients Bilaterally Implanted With Nanoflex Intraocular Lenses
Phase 4
- Conditions
- Patients Who Have Bilateral NanoFlex Implantation at Least 3 Months Previously
- Registration Number
- NCT01279122
- Lead Sponsor
- Innovative Medical
- Brief Summary
The purpose of this study is to look at how well you see the Nanoflex Intraocular lens placed in your eye.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Male or female patients at least 18 years of age.
- Patients who have bilateral NanoFlex implantation at least 3 months previously.
- No significant ocular pathology causing DCVA to be less than 20/25 or causing significant visual loss.
- DCVA of 20/25 or better in both eyes.
- Spherical equivalent in the dominant eye to be +/-.50 or less and in the non-dominant eye to be between-1.00 and -1.87.
- Uncorrected VA in dominant eye 20/25 or better.
Exclusion Criteria
- History of ocular trauma or prior ocular surgery (minor ocular trauma is allowed such as small superficial corneal scar not effecting vision; some prior ocular surgery is allowable so long as it has not impacted visual acuity.
- Amblyopia or strabismus, significant visual field loss, or posterior capsular opacifcation.
- Known pathology that may affect visual acuity; particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Uncorrected Near Visual Acuity 1 year
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the long-term visual outcomes of monovision correction using Nanoflex intraocular lenses compared to multifocal IOLs in presbyopic patients?
How does the aspheric design of Nanoflex intraocular lenses affect contrast sensitivity and higher-order aberrations in monovision patients?
What biomarkers correlate with successful monovision adaptation after bilateral implantation of Nanoflex intraocular lenses in cataract surgery patients?
What are the potential adverse events associated with Nanoflex intraocular lenses in monovision configurations and how do they compare to standard monofocal lenses?
How does the refractive outcome of Nanoflex intraocular lenses in monovision compare to other toric intraocular lenses in patients with astigmatism and presbyopia?
Trial Locations
- Locations (1)
Kenneth Lipstock
🇺🇸Richmond, Virginia, United States
Kenneth Lipstock🇺🇸Richmond, Virginia, United StatesAnnie ChristensenContact951-653-5566a.christensen@imedsonline.com